Physicochemical Properties
Molecular Formula | C20H35NO13 |
Molecular Weight | 497.49 |
Exact Mass | 497.21 |
CAS # | 37248-47-8 |
PubChem CID | 443629 |
Appearance | White to off-white solid powder |
Density | 1.7±0.1 g/cm3 |
Boiling Point | 813.7±65.0 °C at 760 mmHg |
Melting Point | 130-135ºC |
Flash Point | 445.9±34.3 °C |
Vapour Pressure | 0.0±6.6 mmHg at 25°C |
Index of Refraction | 1.689 |
LogP | -5.43 |
Hydrogen Bond Donor Count | 12 |
Hydrogen Bond Acceptor Count | 14 |
Rotatable Bond Count | 7 |
Heavy Atom Count | 34 |
Complexity | 697 |
Defined Atom Stereocenter Count | 14 |
SMILES | C1[C@@H]([C@H]([C@@H]([C@H]([C@H]1N[C@H]2C=C([C@H]([C@@H]([C@H]2O)O)O)CO)O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)CO |
InChi Key | JARYYMUOCXVXNK-CSLFJTBJSA-N |
InChi Code | InChI=1S/C20H35NO13/c22-3-6-1-8(12(26)15(29)11(6)25)21-9-2-7(4-23)19(17(31)13(9)27)34-20-18(32)16(30)14(28)10(5-24)33-20/h1,7-32H,2-5H2/t7-,8+,9+,10-,11-,12+,13+,14-,15+,16+,17-,18-,19-,20+/m1/s1 |
Chemical Name | (2R,3R,4S,5S,6R)-2-[(1R,2R,3S,4S,6R)-2,3-dihydroxy-6-(hydroxymethyl)-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]cyclohexyl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol |
HS Tariff Code | 2934.99.9001 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage.(2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
Targets | Antibiotic[1], IC50: 72 μM (trehalase)[2], Ki: 5.893 mM (tyrosinase)[3] |
ln Vitro | Validamycin A (0.5–1 μg/mL; 18 hours) stops A from growing. conidial germination and inhibits flavus [1]. For human bronchial epithelial cells, validamycin A is not cytotoxic [1]. HIS85, HIS244, GLU256, HIS259, and ASN260 are among the residues in the tyrosinase active site that Validamycin A directly binds to [1]. |
Cell Assay |
Cell Proliferation Assay[1] Cell Types: Aspergillus flavus ATCC204304 Tested Concentrations: 0.5 μg/mL, 1 μg/mL Incubation Duration: 18 hrs (hours) Experimental Results: Inhibited the growth of Aspergillus flavus. |
ADME/Pharmacokinetics |
Metabolism / Metabolites In animals, cleavage to glucose and an amine residue. Biological Half-Life Less than or equal to 5 hr |
Toxicity/Toxicokinetics |
Toxicity Data LC50 (rat) > 5,000 mg/m3 Non-Human Toxicity Values LD50 Rat oral > 20,000 mg/kg LD50 Mice oral > 20,000 mg/kg LD50 Rat percutaneous > 5000 mg/kg |
References |
[1]. The Inhibitory Effect of Validamycin A on Aspergillus flavus. Int J Microbiol. 2020; 2020: 3972415. [2]. Effect of validamycins on glycohydrolases of Rhizoctonia solani. J Antibiot (Tokyo). 1987 Apr;40(4):526-32. [3]. The effect of validamycin A on tyrosinase: inhibition kinetics and computational simulation. Int J Biol Macromol. 2013 Apr;55:15-23. |
Additional Infomation |
Validamycin A is a member of the class of validamycins that is (1R,2S,3S,4S,6R)-4-amino-6-(hydroxymethyl)cyclohexane-1,2,3-triol in which the hydroxy group at position 1 has been converted to its beta-D-glucoside and in which one of the hydrogens attached to the nitrogen is replaced by a (1R,4R,5R,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl group. It is the major validamycin produced by Streptomyces hygroscopicus. It has a role as an EC 2.4.1.231 [alpha,alpha-trehalose phosphorylase (configuration-retaining)] inhibitor, an EC 2.4.1.64 (alpha,alpha-trehalose phosphorylase) inhibitor, an EC 3.2.1.28 (alpha,alpha-trehalase) inhibitor and an antifungal agrochemical. It is a member of validamycins, a secondary amino compound, a polyol and an antibiotic fungicide. It is a conjugate base of a validamycin A(1+). Validamycin A has been reported in Streptomyces anthocyanicus, Streptomyces hygroscopicus, and Streptomyces lividans with data available. |
Solubility Data
Solubility (In Vitro) | H2O : 125 mg/mL (251.26 mM) |
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (201.01 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0101 mL | 10.0505 mL | 20.1009 mL | |
5 mM | 0.4020 mL | 2.0101 mL | 4.0202 mL | |
10 mM | 0.2010 mL | 1.0050 mL | 2.0101 mL |